CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit

PR Newswire


NEW YORK
, June 8, 2025 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class Period”), of the important June 24, 2025 lead plaintiff deadline.

So What: If you purchased Avis Budget securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Avis Budget class action, go to https://rosenlegal.com/submit-form/?case_id=38765 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 24, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Avis Budget crafted and implemented a plan to significantly accelerate its fleet rotation in the fourth quarter of 2024; (2) the foregoing acceleration shortened the useful life of the majority of Avis Budget’s vehicles in the Americas segment, thereby reducing their recoverable value; (3) as a result, Avis Budget would be forced to recognize billions of dollars in impairment charges and incur substantial losses; (4) all the foregoing was likely to, and did, have a significant negative impact on Avis Budget’s financial results; (5) accordingly, Avis Budget’s financial and/or business prospects were overstated; and (6) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Avis Budget class action, go to https://rosenlegal.com/submit-form/?case_id=38765 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/car-investors-have-opportunity-to-lead-avis-budget-group-inc-securities-fraud-lawsuit-302475675.html

SOURCE THE ROSEN LAW FIRM, P. A.

The City of Bentonville, AR Renews Partnership with GovDeals to Sell Surplus Properties

The city moves away from traditional newspaper advertising in favor of a global online auction platform

BENTONVILLE, Ark., June 08, 2025 (GLOBE NEWSWIRE) — The City of Bentonville, AR is once again partnering with GovDeals, the leading online marketplace for government agencies to sell real estate, vehicles, equipment, and other items, to resume conducting virtual auctions for the city’s surplus assets. The shift to online auctions addresses the limitations of traditional newspaper advertising, offering broader reach and increased efficiency in connecting with potential buyers globally.

“We are increasing our GovDeals listings because that is where the buyers are,” said City of Bentonville Purchasing Manager Kelsi Frederick. “Online auctions provide us with more opportunities to move inventory and secure funds for local initiatives. This decision reflects our commitment to embracing modern, efficient methods of commerce.”

Since partnering with GovDeals, the City of Bentonville has successfully generated over $429,000 in sales, demonstrating the effectiveness of online auctions in maximizing revenue from surplus assets. Last year alone, auctioning surplus online netted the city over $142,000, underscoring the financial benefits of this partnership.

All forthcoming auctions can be found directly on GovDeals. In order to bid on items from the City of Bentonville or any asset on GovDeals, potential buyers must first create an account and complete the free and easy registration form. New bidder registration can be completed at GovDeals.com/Register.

About GovDeals

GovDeals is the world’s leading marketplace for surplus government and educational assets, ranging from heavy equipment and transportation assets to industrial machinery and real estate properties. GovDeals specializes in surplus disposition technology, partnering with government agencies and related entities to sell “as is, where is” surplus assets, equipment, and materials in a transparent fashion. Sellers can directly launch and manage their listings in just days with more control and lower fees than traditional auction solutions. GovDeals is powered by one of the most experienced and trusted companies in the surplus industry: Liquidity Services (NASDAQ: LQDT), which has supported millions of customers across the globe. GovDeals buyers have direct access to all the surplus assets across Liquidity Services’ network of marketplaces in one centralized location.



Contact:

Angela Jones, GovDeals

(334)-301-7823

[email protected]

IOVA INVESTOR NEWS: Iovance Biotherapeutics, Inc. has been Sued for Securities Fraud – Contact BFA Law before July 14 Deadline (NASDAQ:IOVA)

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Iovance you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit
.

Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities.   The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al., No. 25-cv-04177.

Why was Iovance Sued for Securities Fraud?

Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company’s authorized treatment centers (“ATCs”).

As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance’s ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs.

The Stock Declines as the Truth is Revealed

On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was “revising full-year 2025 revenue guidance.” The Company blamed “recent launch dynamics,” including slow “treatment timelines for new ATCs” and “the variable pace at which ATCs began treating patients,” which “differs from center to center.” Iovance also blamed the poor results on high “patient drop-off” due to inadequate “patient selection” for treatment.

On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit

.

What Can You Do?

If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



FTRE INVESTOR NEWS: Fortrea Holdings Inc. has been Sued for Securities Fraud – Contact BFA Law before August 1 Deadline (NASDAQ:FTRE)

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Fortrea you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit
.

Investors have until August 1, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Fortrea securities.   The case is pending in the U.S. District Court for the Southern District of New York and is captioned Deslande v. Fortrea Holdings Inc., et al., No. 1:25-cv-04630.

Why was Fortrea Sued for Securities Fraud?

Fortrea is a global contract research organization that provides biopharmaceutical product and medical device development solutions. In June 2023, Fortrea was spun off into a standalone, publicly traded company by Labcorp Holdings Inc. (“Labcorp”). In connection with the spin-off, Fortrea entered into several transition services agreements (the “TSAs”), pursuant to which it agreed to pay Labcorp for certain transitional services over a set period.

As alleged, Fortrea discussed the significant cost savings and margin improvements that would result from exiting the TSAs. In truth, Fortrea overstated the cost savings and margin improvement it would achieve by exiting the TSAs, as well as the amount of revenue it would generate from pre-spin projects.

The Stock Declines as the Truth is Revealed

On September 25, 2024, investment bank Jefferies published a report stating that the cost savings Fortrea would achieve from exiting the TSAs were “[n]ot as [m]aterial as [o]ne [m]ight [t]hink.” On this news, the price of Fortrea stock declined $2.73 per share, or over 12%, from a closing price of $22.21 per share on September 24, 2024, to $19.48 per share on September 25, 2024.

Then, on March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, revealing that the company’s pre-spin projects “have less revenue and less profitability than expected for 2025” and that “post-spin work is not coming on fast enough to offset the pre-spin contract economics.” On this news, the price of Fortrea stock declined $3.47 per share, or over 25%, from a closing price of $13.85 per share on February 28, 2025, to $10.38 per share on March 3, 2025, the next trading day.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit

.

What Can You Do?

If you invested in Fortrea you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



OGN INVESTOR NEWS: Organon & Co. has been Sued for Securities Fraud – Contact BFA Law before July 22 Deadline (NYSE:OGN)

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Organon you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/organon-co-class-action
.

Investors have until July 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Hauser v. Organon & Co., et al., No. 25-cv-05322.

Why was Organon Sued for Securities Fraud?

Organon is a global healthcare company focused on women’s health that has historically rewarded its shareholders with a healthy dividend. In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company focused on dermatological conditions. As alleged, while the acquisition increased Organon’s debt, the Company assured investors it would maintain its dividend, which Organon asserted was its “#1 capital allocation priority.”

In truth, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt, ultimately leading the Company to severely cut its dividend.

The Stock Declines as the Truth is Revealed

On May 1, 2025, Organon announced that management reset the Company’s dividend payout from $0.28 per share to $0.02 per share. Organon’s CEO explained that the Company “reset our capital allocation priorities to accelerate progress towards deleveraging” and that “[b]y deleveraging more rapidly, we will continue to strengthen the future prospects of the company.” Organon’s CFO added, “[t]he biggest issues we face . . . relate to managing our leverage and relate to growth. And we need capital to solve both of those issues, and so returning capital to shareholders is right now, less of a priority.”

On this news, the price of Organon stock declined roughly 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/organon-co-class-action

.

What Can You Do?

If you invested in Organon you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/organon-co-class-action

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/organon-co-class-action

Attorney advertising. Past results do not guarantee future outcomes.



CIVI INVESTOR NEWS: Civitas Resources, Inc. has been Sued for Securities Fraud – Contact BFA Law before July 1 Deadline (NYSE:CIVI)

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Civitas Resources, Inc. (NYSE: CIVI) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Civitas you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/civitas-resources-inc
.

Investors have until July 1, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Civitas securities.   The case is pending in the U.S. District Court for the District of New Jersey and is captioned Lin v. Civitas Resources., et al., No. 25-cv-03791.

Why was Civitas Sued for Securities Fraud?

Civitas is an oil and gas exploration and production company with its key assets located in the Denver-Julesburg Basin in Colorado and the Permian Basin in Texas and New Mexico. The complaint alleges that Civitas stated that both basins had “enhanced recovery potential” and that it had “driven production ahead of plans,” while touting “enhanced margins through reduced operating costs” and insisting that “costs are below expectations.”

In truth, the Company’s oil production peaked in 2024, and increasing production would require Civitas to spend significant capital to acquire additional land, driving up costs.

The Stock Declines as the Truth is Revealed

On February 24, 2025, Civitas announced disappointing Q4 and full year 2024 results, and reduced its oil production guidance. The Company explained that oil production had peaked and it would need to spend hundreds of millions of dollars to acquire thousands of acres of new land to produce more oil. Civitas also announced that it was implementing a 10% reduction in its workforce to “solidify the Company’s low-cost structure.” On the same day, Civitas announced the immediate firings of its Chief Operating Officer and Chief Transformation Officer. On this news, the price of Civitas stock declined more than 18%, from a closing price of $49.30 per share on February 24, 2025, to $40.35 per share on February 25, 2025.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/civitas-resources-inc

.

What Can You Do?

If you invested in Civitas you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/civitas-resources-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/civitas-resources-inc

Attorney advertising. Past results do not guarantee future outcomes.



RDDT INVESTOR NEWS: Reddit, Inc. is being Investigated for Securities Fraud – Contact BFA Law (NYSE:RDDT)

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Reddit, Inc. (NYSE: RDDT) for potential violations of the federal securities laws.

If you invested in Reddit, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/reddit-inc-securities-fraud-class-action.

Why is Reddit being Investigated?

Reddit owns and operates the eponymous social news aggregation, forum, and social media platform. Reddit receives a significant portion of its user traffic from individuals seeking answers to questions using Google Search. During the relevant period, Reddit assured investors that Google’s use of Artificial Intelligence (“AI”) in Google’s search results did not have a material impact on Reddit’s user growth.

In truth, Google’s use of AI dented Reddit’s user growth by eliminating the need for individuals to visit and click through to Reddit to get answers to their questions. Rather, the answers appeared through Google’s AI search results.

The Stock Declines as the Truth is Revealed

On May 21, 2025, Wall Street analyst Baird cut its Reddit stock price target over concerns that Google’s AI capabilities are stifling Reddit’s user growth. On this news, the price of Reddit stock fell $9.79 per share, or over 9%, from $105.64 per share on May 20, 2025, to $95.85 per share on May 21, 2025.

Click here for more information:

https://www.bfalaw.com/cases-investigations/reddit-inc-securities-fraud-class-action

.

What Can You Do?

If you invested in Reddit you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/reddit-inc-securities-fraud-class-action

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/reddit-inc-securities-fraud-class-action

Attorney advertising. Past results do not guarantee future outcomes.



ELV INVESTOR NEWS: Elevance Health, Inc. has been Sued for Securities Fraud – Contact BFA Law before July 11 Deadline (NYSE:ELV)

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Elevance you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/elevance-health-inc
.

Investors have until July 11, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Elevance common stock.   The case is pending in the U.S. District Court for the Southern District of Indiana and is captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092.

Why was Elevance Sued for Securities Fraud?

Elevance provides health insurance plans. This includes contracting with states to administer Medicaid benefits. States routinely review Medicaid eligibility, but during COVID, the federal government paused this process. The pause ended in 2023, and states resumed redetermining Medicaid eligibility.

During the relevant period, Elevance represented that it was closely monitoring the cost trends associated with the redetermination process and that the rates Elevance was negotiating were sufficient to address the risk profiles of those patients staying on Medicaid.

As alleged, in truth, the redeterminations caused a significant increase in the acuity and utilization of Elevance’s Medicaid members. What’s more, the shift occurred to a degree that was not reflected in Elevance’s rate negotiations or in its financial guidance for 2024.

The Stock Declines as the Truth is Revealed

On July 17, 2024, Elevance stated that it was now “expecting second-half utilization to increase in Medicaid” and that it was “seeing signs of increased utilization across the broader Medicaid population.” On this news, the price of Elevance stock declined $32.21 per share, or nearly 6%, from $553.14 per share on July 16, 2024, to $520.93 per share on July 17, 2024.

Then, on October 17, 2024, Elevance announced its Q3 2024 financial results, revealing that its missed consensus earnings per share (“EPS”) expectations by $1.33, or 13.7%, “due to elevated medical costs in [its] Medicaid business.” On this news, the price of Elevance stock declined $52.61 per share, or nearly 11%, from $496.96 per share on October 16, 2024, to $444.35 per share on October 17, 2024.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/elevance-health-inc

.

What Can You Do?

If you invested in Elevance you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/elevance-health-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/elevance-health-inc

Attorney advertising. Past results do not guarantee future outcomes.



URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN)

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in UroGen you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit
.

Investors have until July 28, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased UroGen securities.   The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Cockrell v. UroGen Pharma Ltd., et al., No. 3:25-cv-06088.

Why was UroGen Sued for Securities Fraud?

UroGen develops treatments for specialty cancers. The Company’s lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer. One of the Phase 3 trials for UGN-102 is named ENVISION. As alleged, UroGen stated that the ENVISION trial met its primary endpoint and that UroGen had reached “agreement with the FDA” that the ENVISION trial would support an NDA submission.

In truth, the FDA had previously expressed significant concerns to UroGen regarding the ENVISION trial, which lacked a concurrent control arm.

The Stock Declines as the Truth is Revealed

On May 16, 2025, the FDA published a briefing document stating that it doubted whether the submitted data was sufficient to conclude that UGN-102 was effective. FDA stated that because “ENVISION lacked a concurrent control arm,” the primary endpoints were “difficult to interpret” and that UroGen “chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.” On this news, the price of UroGen stock declined $2.54 per share, or nearly 26%, from a closing price of $9.85 per share on May 15, 2025, to $7.31 per share on May 16, 2025.

Then, on May 21, 2025, the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA, finding that the overall benefit-risk profile of UGN-102 was not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. On this news, the price of UroGen stock declined $3.37 per share, or nearly 45%, from a closing price of $7.54 per share on May 20, 2025, to $4.17 per share on May 21, 2025.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit

.

What Can You Do?

If you invested in UroGen you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



CODI INVESTOR NEWS: Compass Diversified Holdings has been Sued for Securities Fraud – Contact BFA Law before July 8 Deadline (NYSE:CODI)

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Compass Diversified Holdings and Compass Group Diversified Holdings, LLC (NYSE: CODI) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Compass you are encouraged to obtain additional information by visiting

https://www.bfalaw.com/cases-investigations/compass-diversified-holdings
.

Investors have until July 8, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Compass securities.   The case is pending in the U.S. District Court for the Central District of California and is captioned Matthews v. Compass Group Diversified Holdings, Inc., et al., No. 25-cv-981.

Why was Compass Sued for Securities Fraud?

Compass is a statutory trust that acquires and manages a group of small and middle-market businesses. This includes Lugano Holdings, Inc., a designer, manufacturer, and marketer of high-end jewelry. The complaint alleges that the Company’s fiscal 2024 financial statements contained material misstatements relating to unrecorded financing arrangements and irregularities identified in sales, cost of sales, inventory, and accounts receivable recorded by Lugano.

The Stock Declines as the Truth is Revealed

On May 7, 2025, after the market closed, Compass announced that investors should not rely on its fiscal 2024 financial statements amid an ongoing internal investigation, led by outside counsel and a forensic accounting firm, into Lugano. The Company stated that it has “preliminarily identified irregularities in Lugano’s non-CODI financing, accounting, and inventory practices.” The Company also announced that it intended to delay the filing of its Q1 2025 financial results, and that Lugano’s founder and CEO, Moti Ferder, resigned from his positions at Lugano and will not receive any severance compensation. On this news, the price of Compass stock declined roughly 62%, from $17.25 per share on May 7, 2025, to $6.55 per share on May 8, 2025.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/compass-diversified-holdings

What Can You Do?

If you invested in Compass you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/compass-diversified-holdings

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/compass-diversified-holdings

Attorney advertising. Past results do not guarantee future outcomes.